An interventional study of ITP in Lymphedema, sponsored by Huntington Memorial Hospital. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by Huntington Memorial Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.
Among the 168 studies in Lymphedema with a site in United States, this one is the 103rd largest by enrollment of the 122 interventional ones that give a count, is one of 5 that started in 2013, is one of 86 with no phase, and was the 72nd registered.
529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.
Browse Lymphedema studies →37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
Tactile Medical · Sites in United States
Ages 18+
University Hospital, Basel, Switzerland · Sites in United States, Austria, Canada and 8 more countries
Ages 18+
University of South Florida · Sites in United States
Ages 18–75 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 22 · Phase 3 4 · Phase 4 4
First in 2001; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 52 across 369 interventional studies indexed under Lymphedema.
Median enrollment 50 across the 122 interventional studies, 148 across the 44 observational. Of the 114 that completed or were terminated, 39 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 168 have an industry lead sponsor. The 10 most frequent:
Huntington Memorial Hospital is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Huntington Memorial Hospital has 1 study filed under Lymphedema — fewer than ten, so there is no comparison to draw.
12 of the studies in Lymphedema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825157Stanford UniversityEvaluation of Combination Therapy for Upper Extremity Lymphedema | 2027-01-01 |
| NCT02743858Memorial Sloan Kettering Cancer CenterLymphedema Surveillance Study | 2027-04 |
| NCT07012642Advanced Reconstructive Surgery AllianceEfficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema | 2027-04-09 |
| NCT05366699Stanford UniversityLYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | 2027-06-01 |
| NCT05182229Abramson Cancer Center at Penn MedicineComparing Two Ways to Manage Head and Neck Lymphedema | 2027-06-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 168 studies in Lymphedema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction: Breast cancer women who are treated with axillary node dissection are at increased risk for lymphedema - the lifetime risk in these women is estimated at 15-50% and the risk can significantly increase with chemotherapy and radiation therapy
Objectives:
Design: the exploratory study aims to evaluate the feasibility and benefits of the integrative therapy program (ITP) intervention post-operatively for 18 months.
Subjects: Women with breast cancer treated with axillary node dissection with normal baseline pre-operative bioimpedance (L-dex U400) score.
Sample size: 30 subjects
Recruitment and Intervention:
The study participants are recruited by their breast surgeon after they undergo axillary node dissection surgery. 4-6 weeks following surgery, the participants will receive a combination of acupuncture and self management education .
Contents of self-management education include:
Outcome measurements include: L-Dex U400 measurement, arm circumference, pain scale, self-efficacy, and lymphedema knowledge, and Functional Assessment of Cancer Therapy-Breast FACT-B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase. Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks. Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits
Other: ITP
The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit. Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points
Also known as: Integrative Therapy Program
Bioimpedance (L-dex U400)
use L-dex machine
Time frame: 18 months
Arm circumference measurements of the upper limbs using at 4 cm interval
measure the circumference in centimeters
Time frame: 18 months
Self-Efficacy Scale
questionnaires
Time frame: 18 months
Lymphedema Knowledge Scale
questionnaires
Time frame: 18 months
Quality of Life (Functional Assessment of Cancer Therapy-Breast)
survey
Time frame: 18 months
Wong-Baker FACES Pain Scale
1-10 scale
Time frame: 18 months
Plan to share: No
Ran from Aug 2013 to primary completion in Aug 2015, 24 months.
Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's 24 months is below that.
Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huntington Memorial Hospital